Transcript Slide 1

Tenofovir
CAPRISA 004
1% tenofovir vaginal gel
39%
HIV-1
51%
HSV-2
“Life is really simple, but we insist on
making it complicated.”
Confucius
Coinfection of human lymphoid tissue ex vivo
Recto-sigmoid
HIV-1
HSV and other viruses
Tenofovir suppresses HSV-2 in the presence of HIV-1
HSV-2G
HIV-1LAI.04
Tenofovir 200 μM
HIV-1 p24 (10-3/mL)
HSV-2G replication
(log10 copies/mL)
Tenofovir 200 μM
+
-
+
+
+
+
-
+
+
+
3
2
1
0
Tenofovir
Oral
Local
Tenofovir
Tenofovir-diphosphate
IC50 =4.3 µM
HIV-1 RT
IC50 =1.3 µM
HSV DNA polymerase
HCV
HSV
OTHER
HIV
Tenofovir
Acyclovir
CONCLUSIONS
Tenofovir is a dual-targeted
drug that suppresses both
HIV-1 and HSV replication.
Tenofovir at concentrations generated during oral drug
administration that may (or may not) inhibits HIV
transmission are substantially lower than those necessary
to inhibit herpes-simplex viruses.
In general, these findings argue that “marginal” antiviral
activities of a variety of existing drugs should be revisited
to test for possibly missed antiviral activities since in
topical applications these drugs may constitute new
microbicides with dual or multiple antiviral properties.
Andrea Lisco
Christophe Vanpouille,
Andrea Introini
NICHD, NIH
Graciela Andrei, Robert Snoeck,
Joost van den Oord,
Jan Balzarini
Rega Institute
Emanuela Balestra,
Carlo-Federico Perno
University of Roma
Tor Vergata,
Tomas Cihlar
Gilead Sciences, Inc.